Table 2 Univariate analysis and multivariate analysis on OS and PFS in stage IV NSCLC with MPE.

From: Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion

Characteristics

OS

PFS

Univariate

Multivariate

Univariate

Multivariate

P

HR

95% CI

P

P-value

HR

95% CI

P

Age (≤70/>70)

0.069

1.077

0.725–1.599

0.714

0.915

1.017

0.723–1.431

0.924

Male

0.001

1.634

1.122–2.380

0.010

0.001

1.420

0.938–2.149

0.098

Smoking status (ever/never)

0.118

   

0.007

1.105

0.744–1.639

0.621

Histology (Adenocarcinoma/Squamous cell)

0.019

1.026

0.592–1.780

0.927

0.023

1.109

0.671–1.833

0.687

Driver mutation (Positive/Negative)

0.064

   

0.048

1.187

0.738–1.909

0.479

ECOG (0–1/≥2)

0.065

   

0.051

   

T stage (1–2/3–4)

0.401

   

0.290

   

N stage (0–2/3)

0.570

   

0.929

   

M stage (M1a/M1b)

0.309

   

0.584

   

Treatment (1st line)

    Conventional chemotherapy

<0.001

—

—

<0.001

 

—

—

 

    Targeted therapy

0.159

0.770

0.497–1.191

0.240

0.023

0.739

0.447–1.220

0.237

    Supportive care only

<0.001

12.80

5.44–30.13

<0.001

none

   

Hemoglobin, g/dL (<12/≥12)

<0.001

1.905

1.157–3.134

0.011

0.001

2.169

1.363–3.452

0.001

Platelet, per uL (<300,000/≥300,000)

0.017

1.221

0.824–1.809

0.320

0.015

1.334

0.966–1.841

0.080

Albumin, g/dL (<3.1/≥3.1)

<0.001

1.873

1.227–2.860

0.004

0.043

1.050

0.681–1.617

0.826

CRP, mg/dL (<2.68/≥2.68)

<0.001

1.816

1.223–2.697

0.003

0.039

1.279

0.918–1.782

0.147

Platelet/ Lymphocyte (<181.2/≥181.2)

<0.001

2.161

1.457–3.204

<0.001

0.094

   
  1. BMI: body mass index; CI: confidence interval; CRP: c-reactive protein; ECOG: Eastern Cooperative Oncology Group; HR: hazard ratio; LDH: lactate dehydrogenase; OS: overall survival; PFS: progression free survival.
Back to article page